O2Micro Reports Third Quarter 2016 Financial Results
Nov 02, 2016 12:01 pm UTC| Business
GEORGE TOWN, Grand Cayman, Nov. 02, 2016 -- Operational and Strategic Highlights: O2Micro reports non-GAAP net income per fully diluted ADS of 0.07 and GAAP net income per fully diluted ADS of $0.05Company...
O2Micro Reports Third Quarter 2016 Financial Results
Nov 02, 2016 12:01 pm UTC| Business
GEORGE TOWN, Grand Cayman, Nov. 02, 2016 -- Operational and Strategic Highlights: O2Micro reports non-GAAP net income per fully diluted ADS of 0.07 and GAAP net income per fully diluted ADS of $0.05Company...
Nov 02, 2016 12:01 pm UTC| Business
Pilot Study Designed to Enable Progression to Larger Phase 2 Trial to Finalize Dosing and Endpoints Prior to Single Pivotal Study Trial Will Assess 12-week Safety and Tolerability in Outpatient Setting; Topline Data...
Nov 02, 2016 12:01 pm UTC| Business
Pilot Study Designed to Enable Progression to Larger Phase 2 Trial to Finalize Dosing and Endpoints Prior to Single Pivotal Study Trial Will Assess 12-week Safety and Tolerability in Outpatient Setting; Topline Data...
CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9
Nov 02, 2016 12:01 pm UTC| Business
NEWARK, Calif., Nov. 02, 2016 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today...
CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9
Nov 02, 2016 12:01 pm UTC| Business
NEWARK, Calif., Nov. 02, 2016 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today...
Calithera Biosciences to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
Nov 02, 2016 12:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor...